Profile data is unavailable for this security.
About the company
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
- Revenue in USD (TTM)0.00
- Net income in USD-7.07m
- Incorporated2023
- Employees9.00
- LocationMymd Pharmaceuticals Inc855 N. Wolfe Street, Suite 601BALTIMORE 21205United StatesUSA
- Websitehttps://www.mymd.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pineapple Inc | 157.59k | 376.69k | 4.75m | -- | 0.5834 | -- | 12.47 | 30.15 | 0.1114 | 0.1114 | 0.0028 | -0.0318 | 0.0388 | -- | -- | -- | 9.28 | -- | 53.43 | -- | -412.55 | -- | 239.03 | -- | 0.00 | -- | -- | -- | -- | -- | -611.10 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -19.04m | 4.82m | 21.00 | -- | 0.1524 | -- | -- | -1.15 | -1.15 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -32.65 | -36.95 | -37.33 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Azitra Inc | 572.70k | -12.40m | 4.85m | 10.00 | -- | 1.12 | -- | 8.47 | -2.87 | -2.87 | 0.0492 | 0.1501 | 0.0977 | -- | 11.54 | 57,270.00 | -200.61 | -- | -287.43 | -- | -- | -- | -2,053.34 | -- | -- | -129.02 | 0.0085 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| AccuStem Sciences Inc | 0.00 | -1.74m | 4.88m | 3.00 | -- | -- | -- | -- | -0.1537 | -0.1537 | 0.00 | -0.2309 | 0.00 | -- | -- | 0.00 | -1,168.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 45.26 | -- | -- | -- |
| Soligenix Inc | 699.21k | -7.01m | 4.90m | 13.00 | -- | 4.25 | -- | 7.00 | -0.7395 | -0.7395 | 0.0725 | 0.073 | 0.073 | -- | 4.17 | 53,785.38 | -73.17 | -75.40 | -2,448.34 | -154.32 | 9.46 | 22.83 | -1,002.55 | -620.02 | -- | -- | 0.7959 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Emmaus Life Sciences Inc | 28.46m | -4.74m | 4.93m | 55.00 | -- | -- | -- | 0.1734 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 4.94m | 5.00 | -- | 1.79 | -- | 10.35 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 4.96m | 9.00 | -- | 0.2193 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 5.10m | 12.00 | -- | 1.67 | -- | 55.04 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| Biofrontera Inc | 33.25m | -23.09m | 5.11m | 85.00 | -- | -- | -- | 0.1538 | -12.47 | -12.47 | 16.84 | -0.3627 | 0.9995 | 2.50 | 5.75 | 391,200.00 | -69.40 | -- | -144.06 | -- | 48.99 | -- | -69.44 | -- | 0.944 | -3.55 | 4.63 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -9.83m | 5.12m | 13.00 | -- | 0.5755 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Synaptogenix Inc | 0.00 | -12.23m | 5.13m | 5.00 | -- | 0.2047 | -- | -- | -37.38 | -37.38 | 0.00 | 21.08 | 0.00 | -- | -- | 0.00 | -13.75 | -40.33 | -15.54 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| HST Global Inc | 0.00 | -146.22k | 5.14m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
| Ainos Inc | 93.68k | -14.56m | 5.16m | 46.00 | -- | 0.2226 | -- | 55.10 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Stemtech Corp | 4.64m | -4.08m | 5.17m | 45.00 | -- | -- | -- | 1.11 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Mymd Pharmaceuticals Inc's reporting currency: US Dollar USD
42.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Global X Management Co. LLCas of 31 Mar 2024 | 875.93k | 40.60% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 30.35k | 1.41% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.56k | 0.30% |
| Iroquois Capital Management LLCas of 31 Dec 2023 | 6.25k | 0.29% |
| UBS Securities LLCas of 31 Mar 2024 | 1.96k | 0.09% |
| Bridgecreek Investment Management LLCas of 31 Dec 2023 | 1.00k | 0.05% |
| Parallel Advisors LLCas of 31 Mar 2024 | 838.00 | 0.04% |
| Group One Trading LPas of 31 Mar 2024 | 459.00 | 0.02% |
| Vanguard Global Advisers LLCas of 31 Mar 2024 | 310.00 | 0.01% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 247.00 | 0.01% |
More ▼
Data from 31 Dec 2023 - 22 May 2024Source: FactSet Research Systems Inc.
